Pfizer Inc
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer FSME-IMMUN / TicoVac by Year
FSME-IMMUN / TicoVac (tick-borne encephalitis vaccine) — U.S. revenues ($M) ($M)
Pfizer FSME-IMMUN / TicoVac: $3M in FY2025, unchanged from a year earlier.
Where the FY2025 figure comes from
“|| FSME-IMMUN/TicoVac | 319 | 280 | 14% | 10% | 3 | 3 | 13% | 316 | 277 | 14% | 10%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | FSME-IMMUN / TicoVac (tick-borne encephalitis vaccine) — U.S. revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | 0.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 3 | 0.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 3 | +50.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 2 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
Breakdown
What makes up FSME-IMMUN / TicoVac
Cite this data
StockData. (2026). Pfizer FSME-IMMUN / TicoVac ($M), annual FY2022–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/fsme-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.